VRTX|Vertex Pharmaceuticals Inc|Preço:477.900|Var. %:19.09

Mais detalhes de Vertex Pharmaceuticals Inc Empresa

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).

Informações de Vertex Pharmaceuticals Inc



Código da empresaVRTX

Nome da EmpresaVertex Pharmaceuticals Inc

Data de listagemJul 24, 1991

CEOKewalramani (Reshma)

Número de funcionários6100

Tipo de títulosOrdinary Share

Fim do ano fiscalJul 24

Endereço50 Northern Avenue

CidadeBOSTON

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal02210

Telefone16173416393

Sitehttps://www.vrtx.com/

Código da empresaVRTX

Data de listagemJul 24, 1991

CEOKewalramani (Reshma)

Executivos da empresa Vertex Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

Mr. Duncan Mckechnie

Executive Vice President, Chief Commercial Officer

22.93K

+6800.00%

Mr. Lloyd A. Carney

Independent Director

6.32K

-800.00%

Dr. Sangeeta N. Bhatia, M.D., Ph.D.

Independent Director

4.57K

-266.00%

Ms. Jennifer J. Schneider

Independent Director

1.72K

+796.00%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. Reshma Kewalramani

President, Chief Executive Officer, Director

90.67K

+38857.00%

Mr. Bruce I. Sachs

Lead Independent Director

45.00K

+5000.00%

Dr. Carmen Bozic, M.D.

Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer

44.00K

+11333.00%

Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.

Executive Chairman of the Board

33.48K

+9012.00%

Dr. Ourania (Nia) Tatsis, Ph.D.

Executive Vice President, Chief Regulatory and Quality Officer

33.05K

+7249.00%

Mr. Jonathan Biller, J.D.

Executive Vice President, Chief Legal Officer

24.37K

+9068.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

FY2018

Por EmpresaUSD

Nome

Receita

Proporção

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

Por RegiãoUSD

Nome

Receita

Proporção

United States

1.98B

64.24%

Europe

836.90M

27.20%

Other

263.20M

8.56%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

TRIKAFTA

2.65B

86.26%

ALYFTREK

247.00M

8.03%

Other CF products

175.80M

5.71%

Distribuição de ações

Atualizado em: sáb, 15 de nov

Investidores

Tipos de investidores

Investidores

Proporção

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

Outro

63.53%

Investidores

Proporção

Capital World Investors

10.21%

The Vanguard Group, Inc.

9.45%

Capital Research Global Investors

6.52%

BlackRock Institutional Trust Company, N.A.

5.70%

State Street Investment Management (US)

4.57%

Outro

63.53%

Tipos de investidores

Investidores

Proporção

Investment Advisor

60.43%

Investment Advisor/Hedge Fund

27.86%

Research Firm

2.35%

Pension Fund

2.35%

Bank and Trust

2.10%

Sovereign Wealth Fund

1.50%

Hedge Fund

1.14%

Individual Investor

0.19%

Insurance Company

0.06%

Outro

2.00%

Participação acionária institucional



Atualizado em: qui, 1 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

2986

248.55M

97.96%

-4.86M

2025Q3

2933

249.27M

98.24%

-2.14M

2025Q2

2933

252.71M

98.56%

+2.47M

2025Q1

2977

252.24M

98.22%

-39.54K

2024Q4

2877

248.76M

96.87%

-2.25M

2024Q3

2786

247.87M

96.18%

-4.19M

2024Q2

2747

248.36M

96.27%

-4.14M

2024Q1

2680

247.63M

95.87%

-4.48M

2023Q4

2608

247.92M

96.20%

-4.51M

2023Q3

2477

248.64M

96.45%

-6.19M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

Capital World Investors

25.91M

10.21%

-2.82M

-9.82%

Sep 30, 2025

The Vanguard Group, Inc.

24.10M

9.5%

+240.67K

+1.01%

Sep 30, 2025

Capital Research Global Investors

16.55M

6.52%

+444.99K

+2.76%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

14.47M

5.7%

+317.50K

+2.24%

Sep 30, 2025

State Street Investment Management (US)

11.61M

4.57%

-169.23K

-1.44%

Sep 30, 2025

Geode Capital Management, L.L.C.

5.97M

2.35%

+45.00K

+0.76%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

5.69M

2.24%

+318.09K

+5.92%

Dec 31, 2025

Wellington Management Company, LLP

4.77M

1.88%

-41.34K

-0.86%

Sep 30, 2025

Capital International Investors

4.69M

1.85%

+2.05M

+77.89%

Sep 30, 2025

AllianceBernstein L.P.

4.52M

1.78%

+144.27K

+3.30%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sex, 5 de dez

Nome

Proporção

VanEck Biotech ETF

9.71%

ProShares Ultra Nasdaq Biotechnology

8.83%

Invesco Nasdaq Biotechnology ETF

8.76%

iShares Biotechnology ETF

7.43%

Invesco Biotechnology & Genome ETF

5.35%

Natixis Loomis Sayles Focused Growth ETF

4.48%

First Trust NASDAQ Pharmaceuticals ETF

4.23%

First Trust NYSE Arca Biotechnology Index Fund

3.5%

Franklin Genomic Advancements ETF

3.33%

Simplify Health Care ETF

3.25%

Ver Mais

VanEck Biotech ETF

Proporção9.71%

ProShares Ultra Nasdaq Biotechnology

Proporção8.83%

Invesco Nasdaq Biotechnology ETF

Proporção8.76%

iShares Biotechnology ETF

Proporção7.43%

Invesco Biotechnology & Genome ETF

Proporção5.35%

Natixis Loomis Sayles Focused Growth ETF

Proporção4.48%

First Trust NASDAQ Pharmaceuticals ETF

Proporção4.23%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.5%

Franklin Genomic Advancements ETF

Proporção3.33%

Simplify Health Care ETF

Proporção3.25%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Sem dados

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados